Announced
Completed
Financials
Sources
Tags
Majority
Acquisition
vaccines
Friendly
Single Bidder
Private
Czechia
Biotechnology
Cross Border
Completed
Synopsis
Novavax, an American vaccine development company, completed the acquisition of Praha Vaccines, a Czech vaccination company, for c.$167m. “Manufacturing capacity is a critical component of our strategy to deliver a vaccine for the Covid-19 pandemic. This acquisition provides the vital assets required to produce more than 1bn doses per year. In parallel with ramping up production at Bohumil, we will continue efforts to expand antigen capacity in the US and Asia, and increase the production of Matrix-M to match antigen capacity at multiple sites globally,” Stanley C. Erck, Novavax President and Chief Executive Officer.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.